Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Finkelman RD"" wg kryterium: Autor


Wyświetlanie 1-13 z 13
Tytuł:
Letter to the editor: re: 'clinical guidelines of the italian society of periodontology for the reconstructive surgical treatment of angular bony defects in periodontal patients'.
Autorzy:
Finkelman RD
Pokaż więcej
Źródło:
Journal of Periodontology; Mar2009, Vol. 80 Issue 3, p363-363, 1p
Czasopismo naukowe
Tytuł:
A Pharmacokinetic Bridging Study to Compare Systemic Exposure to Budesonide between Budesonide Oral Suspension and ENTOCORT EC in Healthy Individuals.
Autorzy:
Song IH; Shire Human Genetic Therapies, Inc., a Member of the Takeda Group of Companies, 300 Shire Way, Lexington, MA, 02421, USA. .
Finkelman RD; Shire Human Genetic Therapies, Inc., a Member of the Takeda Group of Companies, 300 Shire Way, Lexington, MA, 02421, USA.
Lan L; Shire Human Genetic Therapies, Inc., a Member of the Takeda Group of Companies, 300 Shire Way, Lexington, MA, 02421, USA.
Pokaż więcej
Źródło:
Drugs in R&D [Drugs R D] 2020 Dec; Vol. 20 (4), pp. 359-367. Date of Electronic Publication: 2020 Oct 15.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
MeSH Terms:
Anti-Inflammatory Agents/*administration & dosage
Anti-Inflammatory Agents/*pharmacokinetics
Budesonide/*administration & dosage
Budesonide/*pharmacokinetics
Eosinophilic Esophagitis/*drug therapy
Administration, Oral ; Adolescent ; Adult ; Anti-Inflammatory Agents/adverse effects ; Biological Availability ; Budesonide/adverse effects ; Clinical Trials, Phase III as Topic ; Cross-Over Studies ; Female ; Humans ; Male ; Middle Aged ; Suspensions ; Tablets, Enteric-Coated ; Young Adult
Czasopismo naukowe
Tytuł:
In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes.
Autorzy:
Chen N; a Drug Metabolism and Pharmacokinetics, Research and Nonclinical Development , Shire , Lexington , MA , USA.
Cui D; a Drug Metabolism and Pharmacokinetics, Research and Nonclinical Development , Shire , Lexington , MA , USA.
Wang Q; b Absorption Systems , Exton , PA , USA , and.
Wen Z; b Absorption Systems , Exton , PA , USA , and.
Finkelman RD; c Clinical Pharmacology & Pharmacokinetics, Shire , Lexington , MA , USA.
Welty D; a Drug Metabolism and Pharmacokinetics, Research and Nonclinical Development , Shire , Lexington , MA , USA.
Pokaż więcej
Źródło:
Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2018 Jun; Vol. 48 (6), pp. 637-646. Date of Electronic Publication: 2017 Jul 21.
Typ publikacji:
Journal Article
MeSH Terms:
Budesonide/*pharmacokinetics
Budesonide/*pharmacology
Carrier Proteins/*metabolism
Cytochrome P-450 Enzyme System/*metabolism
Hepatocytes/*metabolism
Microsomes, Liver/*enzymology
Cells, Cultured ; Drug Interactions ; Hepatocytes/cytology ; Humans
Czasopismo naukowe
Tytuł:
Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjects.
Autorzy:
Finkelman RD; AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.
Wang TD; Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan.
Wang Y; Purdue Pharma, Stamford, CT, USA.
Azumaya CT; AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA.
Birmingham BK
Wissmar J; AstraZeneca Pharmaceuticals, Mölndal, Sweden.
Mosqueda-Garcia R; Covance Inc., Princeton, NJ, USA.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2015 Jan; Vol. 4 (1), pp. 33-40. Date of Electronic Publication: 2014 Aug 28.
Typ publikacji:
Clinical Trial; Journal Article
MeSH Terms:
Pharmacogenomic Variants*
Polymorphism, Genetic*
Cytochrome P-450 CYP2C19/*genetics
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacokinetics
Rosuvastatin Calcium/*pharmacokinetics
Administration, Oral ; Adult ; Aged ; Area Under Curve ; Asian People ; Biotransformation ; Cytochrome P-450 CYP2C19/metabolism ; Drug Administration Schedule ; Female ; Genotype ; Healthy Volunteers ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/blood ; Male ; Middle Aged ; Pharmacogenetics ; Pharmacogenomic Testing ; Phenotype ; Pyrimidines/pharmacokinetics ; Rosuvastatin Calcium/administration & dosage ; Rosuvastatin Calcium/adverse effects ; Rosuvastatin Calcium/blood ; Sulfonamides/pharmacokinetics ; Taiwan ; Young Adult
Czasopismo naukowe
    Wyświetlanie 1-13 z 13

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies